Arcutis (ARQT) Q2 2026 earnings review
Growth Reaccelerates, Profitability Returns, Guidance Raised
Arcutis delivered a massive Q2, erasing the seasonal stumble of Q1. Revenue surged 59% YoY and 23% sequentially to $129.9M, driven heavily by the ZORYVE foam formulation. Crucially, the company achieved GAAP profitability with $15.0M in net income, reversing the $11.3M loss from Q1 2026. The combination of strong demand, improving gross-to-net pricing, and positive operating cash flow allowed management to confidently raise full-year revenue guidance by roughly 9% at the midpoint. This quarter validates the company's heavy investments in sales force expansion and solidifies ZORYVE's dominance in the non-steroidal topical market.
🐂 Bull Case
The 23% sequential revenue growth proves Q1's decline was purely seasonal. With new primary care and pediatric sales teams hitting the field in Q3, top-line momentum has multiple catalysts to sustain its trajectory.
Despite a massive $82.1M SG&A spend to fund sales expansions, the company still generated $15.0M in net income and $12.6M in operating cash flow. They are successfully self-funding their aggressive growth.
🐻 Bear Case
Arcutis is entirely reliant on the ZORYVE brand, and specifically the 0.3% foam formulation, which now accounts for over 50% of total revenue. Any safety signal or aggressive competitive pricing would be devastating.
SG&A grew nearly 19% YoY to $82.1M. While revenue is currently outpacing this growth, the sheer size of the commercial infrastructure required to penetrate primary care creates a high fixed-cost burden if demand falters.
⚖️ Verdict: 🟢🟢
Strongly Bullish. Arcutis proved its core product is a juggernaut. The return to GAAP profitability, accelerating sequential growth, and a meaningful guidance raise suggest the commercial execution is flawless right now.
Key Themes
Foam Formulation is the Primary Growth Engine
While Arcutis sells multiple ZORYVE variations, the 0.3% Foam is carrying the company. In Q2 2026, foam sales hit $67.4M—accounting for nearly 52% of total product revenue and growing significantly faster than the legacy creams. This validates the strategy of offering alternative vehicles for scalp and body application, proving to be a massive competitive moat against other topicals.
Commercial Infrastructure Expansion
The company has fully built out its primary care and pediatric-focused sales force, with field launch expected by late August. To complement this, they launched a virtual health platform and an AI-enabled healthcare partnership to streamline patient access and physician workflows. This multi-channel approach is designed to aggressively capture the massive, but highly fragmented, primary care market.
Relentless Label Expansion Strategy
Arcutis secured its seventh FDA approval in four years by expanding ZORYVE cream 0.3% down to age 2 for plaque psoriasis. Furthermore, the FDA accepted the sNDA for infants (3-24 months) with atopic dermatitis (PDUFA February 2027). Expanding into vulnerable pediatric populations builds trust with prescribers, which naturally bleeds into higher adult prescription volumes.
Macro Shift Away from Corticosteroids
The overarching tailwind for Arcutis remains the structural shift in dermatology away from long-term topical corticosteroid (TCS) use. With ZORYVE positioned as the premier non-steroidal alternative, the company is capitalizing on a fundamental change in how clinicians manage chronic inflammatory skin diseases.
Pipeline Investment Appears Stagnant
Despite management's narrative around 'building the pipeline', Q2 2026 R&D expenses were $20.4M, essentially flat compared to $19.5M in Q2 2025. While decreased costs for earlier pediatric programs offset new investments in ARQ-234, the lack of R&D spending growth suggests the company is heavily prioritizing near-term commercial profitability over aggressive long-term pipeline development.
Massive SG&A Base Requires Perfect Execution
SG&A expenses hit $82.1M in Q2, up 18.7% YoY. While revenue is growing much faster (59%), spending $82M in a single quarter on SG&A for a $130M revenue base is aggressive. If the new primary care sales team fails to yield accretive demand by late 2026, this fixed cost infrastructure will severely compress operating margins.
Other KPIs
Accelerating significantly from the $2.2M generated in Q1 2026. This sequential improvement proves the company's underlying cash generation capability, reinforcing management's promise to self-fund their growth initiatives without diluting shareholders. The company ended the quarter with a healthy $238.9M in cash and marketable securities.
Management explicitly cited 'improved gross-to-net (GTN) pricing' as a key driver of the sequential revenue growth. This aligns with prior guidance indicating that GTN would improve from the high-50% range in Q1 toward the low-50% range as the year progressed, driven by better formulary positioning and reduced copay assistance.
Guidance
Accelerating. Management raised the full-year guidance from the prior range of $480M-$495M. This $45M raise at the midpoint implies massive confidence in H2 2026 execution. Given H1 2026 revenue is $235.3M, the new midpoint of $532.5M implies H2 2026 revenue of ~$297.2M, requiring an average quarterly run-rate of ~$148M for Q3 and Q4.
Key Questions
Foam vs. Cream Cannibalization
With the 0.3% Foam formulation now making up more than half of total product revenue, are you seeing any cannibalization of the legacy cream business, or is the foam entirely unlocking new patient populations and treatment sites?
SG&A Leverage Inflection Point
SG&A grew to $82.1M this quarter to support the primary care sales force launch. At what quarterly revenue run-rate do you expect to see peak SG&A dollars, and when will operating margins begin to expand more aggressively?
AI and Virtual Health ROI
You announced new virtual health and AI-enabled healthcare platform partnerships. How exactly do these translate into improved gross-to-net pricing or volume, and what is the expected financial contribution of these specific channels in the revised FY26 guidance?
R&D Spend Trajectory
R&D expense was relatively flat year-over-year. As you look to advance ARQ-234 and evaluate the Phase 2 vitiligo/HS data, should we expect a step-up in R&D spending in 2027, or can current cash flows easily absorb late-stage trial costs?